Fernando Cabanillas (25 results)

Paperback. Condition: Fair. Oscar Lopez Rivera (illustrator). First Edition. The item might be beaten up but readable. May contain markings or highlighting, as well as stains, bent corners, or any other major defect, but the text is not obscured in any way.

Condition: New. Idioma/Language: Español. *** Nota: Los envíos a España peninsular, Baleares y Canarias se realizan a través de mensajería urgente. No aceptamos pedidos con destino a Ceuta y Melilla.

Soft cover. Condition: Very Good. No Jacket. Oscar Lopez Rivera (illustrator). 1st Edition. From the private collection of poet, Margaret Randall. Foreword by Martin Espada. In very good condition with clean and tight pages. Letters from political prisoner Oscar Lopez Rivera to his granddaughter, Karina. 212 pages.

Rústica. Condition: Muy Bien. Real Academia de Jurisprudencia y Legislación, Madrid, 1977. Encuadernación en rústica, 240 págs. Dedicatoria autógrafa del autor (Pío Cabanillas). Título y autor escritos en tinta en el lomo, por lo demás en muy buen estado. Dedicatoria autógrafa del auto.

Condition: New.

Condition: New.

Condition: Nuevo. En la obra se ofrece un completo estudio sobre los aspectos más controvertidos y relevantes que plantea la crisis empresarial de las sociedades mercantiles de capital en todos sus estadios, fundamentalmente desde el análisis jurídico concursal, societario y penal utilizando tanto el derecho español como el derecho comparado.El libro se estructura en tres partes: Introducción y Derecho comparado, Derecho preconcursal de sociedades mercantiles de capital y Concurso de acreedores de sociedades mercantiles de capital. Las tres partes comprenden un total de catorce capítulos que persiguen afrontar los temas de mayor enjundia que han sido objeto de discusión teórico-práctica, con el fin de ofrecer soluciones interpretativas a las dudas que plantea el derecho positivo. Todos los trabajos han sido redactados por consumados y prestigiosos especialistas en la materia de cada uno de los estudios, fundamentalmente juristas, aunque también se incluye, abriendo la obra, una valiosa aportación de índole económico-empresarial procedente de un experto en gestión de grandes empresas. Entre los autores procedentes del ámbito jurídico, junto a dominadores del Derecho Concursal y del Derecho de Sociedades, no sólo desde el punto de vista del estudio doctrinal sino también desde la praxis y no sólo españoles sino también italianos, en concreto dos relevantes profesores de la Universidad de Bolonia, asimismo abogados, se integra en el destacado elenco un profesional del Derecho Penal, de dilatada experiencia y también doctor en Derecho. Los estudiosos de las crisis empresariales societarias, profesores y jueces, encontrarán en este libro un referente de ineludible consulta. Asimismo, se trata de una obra capaz de resultar imprescindible acerca del preconcurso y del concurso de sociedades mercantiles de capital para administradores concursales, abogados, economistas e incluso para inversores.

Gebunden. Condition: New.

Condition: New. In.

Condition: New. In.

Condition: New.

Condition: New. pp. 184.

Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results.

Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results.

Paperback. Condition: Like New. Like New. book.

hardcover. Condition: New. In shrink wrap. Looks like an interesting title!

Condition: Usado - bueno.

Condition: ESTADO COMO NUEVO. TAPA BLANDA RUSTICA ILUSTRADA.

Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results. 184 pp. Englisch.

Buch. Condition: Neu. Advances in Lymphoma Research | M. Alma Rodriguez (u. a.) | Buch | xi | Englisch | 1997 | Springer US | EAN 9780792339298 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.

Condition: New. Print on Demand pp. 184 49:B&W 6.14 x 9.21 in or 234 x 156 mm (Royal 8vo) Perfect Bound on White w/Gloss Lam.

Buch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 186 pp. Englisch.

Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 184 pp. Englisch.

Condition: New. PRINT ON DEMAND pp. 184.

Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results. 186 pp. Englisch.